CINGULATE INC. CING 深 滬
已收盤 08-22 16:00:00 美东时间
4.19
+0.200
+5.01%
華盛通- 最 高4.19
- 今 開4.02
- 成交量 13.37万股
- 最 低 3.9525
- 昨 收 3.99
- 總市值 2156.26万
- 52周最高 7.69
- 市盈率 靜 --
- 換手率 2.60%
- 52周最低 3.02
- 委 比 -51.63%
- 總股本 514.62万
- 歷史最高 1236.00
- 量 比 1.17
- 振 幅 5.95%
- 歷史最低 2.574
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.
08-22 17:54
Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) by 29.3 percent. This is a 80.07 percent increase over losses of $(5.47) per share from the
08-19 21:46
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Cingulate Inc. submitted an NDA to the FDA for its lead asset, CTx-1301, a novel ADHD treatment, with an anticipated decision by Q4 2025 and potential approval in mid-2026. The company reported a net loss of $4.8 million in Q2 2025, driven by increased R&D costs linked to the NDA submission. Cash reserves stood at $8.9 million as of June 2025, with plans to raise additional capital for commercialization. The submission follows successful Phase 3 ...
08-19 12:45
Cingulate Inc CEO Shane Schaffer on Administrative Leave
An announcement from Cingulate Inc ( ($CING) ) is now available. On August 9, 2...
08-15 21:28
Cingulate Appoints Jennifer Callahan As Interim CEO; Names Jay Roberts Executive Chairman
Jennifer Callahan, Chief Financial Officer, appointed Interim CEOBoard member, Jay Roberts appointed Executive ChairmanKANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:CING) The Board of Directors of
08-15 21:15
Cingulate Provides Management Team Update
Cingulate Inc. announced that CEO Shane J. Schaffer has been placed on administrative leave due to unrelated legal matters. Jennifer Callahan, CFO, was appointed Interim CEO, retaining her CFO role. Jay Roberts, a board member with extensive healthcare experience, was named Executive Chairman. The company remains committed to advancing its ADHD treatment candidate CTx-1301, recently filing an FDA application. Callahan, joined by experienced execu...
08-15 13:00
ZIONS BANCORPORATION ANNOUNCES PRICING OF SENIOR NOTES
SALT LAKE CITY, Aug. 11, 2025 /PRNewswire/ -- Zions Bancorporation, N.A. (NASDAQ: ZION) announced today that it priced $500,000,000 of fixed-to-floating rate senior notes (CUSIP: 98971DAD2) ...
08-12 05:02
FGI INDUSTRIES ANNOUNCES SECOND QUARTER 2025 RESULTS
EAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- FGI Industries Ltd. (Nasdaq: FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results ...
08-12 04:15
Gen Delivers Double-Digit Growth in Q1 FY26
Gen Raises its Annual Guidance on Better-Than-Expected Results TEMPE, Ariz. and PRAGUE, Aug. 7, 2025 /PRNewswire/ -- Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to powering Dig...
08-08 04:05
Cingulate Inc Submits NDA for ADHD Treatment
Cingulate Inc ( ($CING) ) has provided an announcement. Cingulate Inc. announce...
08-06 21:19
